766 results about "Polyarthritis Rheumatica" patented technology

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The invention relates to an active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation as well as a preparation method and application thereof. Triptolide is coupled with an active oxygen responsive group to synthesize a triptolide derivative; then, the triptolide derivative is coupled with polypeptide, and a polypeptide-reactive oxygen responsive group-triptolide conjugate is obtained; then dissolving the polypeptide-active oxygen responsive group-triptolide conjugate in a solvent, standing, and carrying out self-assembly to obtain a triptolide prodrug nanofiber solution; finally, an immunomodulator is added into the triptolide prodrug nanofiber solution for incubation, and the active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation is obtained. The hydrogel preparation disclosed by the invention can responsively release the medicine triptolide and the immunomodulator at the focus part of rheumatoid arthritis, so that the medicine accumulation of non-target organs is reduced, the safety and effectiveness of treatment are improved, and the progress of diseases is effectively controlled.

The invention provides an organ chip unit for simulating the pathogenesis of rheumatoid arthritis, and belongs to the technical field of cell culture. The chip comprises a top-layer chip, a bottom-layer chip and a middle microporous membrane, the top-layer chip and the bottom-layer chip are separated by the middle microporous membrane, and the middle microporous membrane is used for enabling cells in a cell culture space of the top-layer chip and cells in a cell culture space of the bottom-layer chip not to be in direct contact, but interaction of signal molecules and substance exchange can be carried out; synovial cells and cartilage cells are injected into the bottom-layer chip or the top-layer chip to be cultured. According to the invention, multi-cell three-dimensional co-culture can be realized. Through the additional stress stimulation co-culture part, the influence of pressure or tension on the cell environment can be judged, and the actual condition that rheumatoid arthritis joints receive pressure or tension for a long time can be simulated. The synovial cells and the cartilage cells are used, so that the structure of the inflammation joint in a living body can be truly reflected, and the interaction among various cell tissues can be reflected.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention discloses a method for predicting periprosthetic infection of an artificial joint after a rheumatoid arthritis operation, and belongs to the technical field of medical treatment, the method can be applied to risk prediction of periprosthetic infection (PJI) of the artificial joint after the rheumatoid arthritis operation, and the method comprises the following steps: carrying out feature selection through a Boruta algorithm; an integrated machine learning algorithm is developed based on a genetic algorithm and an SMOTEENN algorithm in combination with machine learning for risk prediction, so that the accuracy and practicability of PJI risk prediction after joint replacement of a rheumatoid arthritis patient are improved. According to the rheumatoid arthritis artificial joint postoperative periprosthetic infection risk prediction method, a more accurate prediction and personalized treatment scheme can be provided for a doctor, and preoperative management of joint replacement of a rheumatoid arthritis patient is optimized, so that PJI is prevented to the greatest extent, and the joint function and life quality of the patient are improved.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a rheumatoid arthritis foot orthopedic and warm-keeping device, and relates to the technical field of arthritis foot orthopedic, the rheumatoid arthritis foot orthopedic and warm-keeping device comprises a bottom plate, the bottom plate is fixedly connected with a shell, one side of the bottom of the shell is rotatably connected with an insertion rod, one end of the insertion rod is fixedly connected with a turnover plate, the upper surface of the turnover plate is provided with two connecting blocks, and the two connecting blocks are fixedly connected with the bottom of the shell. And the upper surface of the other end of the bottom plate is fixedly connected with a front plate. According to the rheumatoid arthritis foot orthopedic and warm-keeping device, in the process that a patient lifts the instep upwards for the first time, a limiting rod slides into a short groove from a long groove, a sliding rod extrudes a force storage spring to enable the force storage spring to form downward thrust, the downward thrust formed by extruding the force storage spring by the sliding rod is larger, and therefore the foot orthopedic effect is improved. When the patient lifts the instep upwards for the second time, the downward thrust of the force storage spring helps the patient to lift the instep, the burden of instep muscles of the patient is relieved through the stored force of the force storage spring, and the effect of protecting the joints of the patient is achieved.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention provides a traditional Chinese medicine composition for treating rheumatic arthritis, a preparation and application, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following medicinal raw materials: 12-18 parts of sailong bone, 6-12 parts of radix aconiti lateralis preparata, 3-9 parts of radix aconiti preparata, 9-15 parts of cassia twig, 1-4 parts of asarum, 9-15 parts of radix clematidis, 20-40 parts of astragalus membranaceus, 3-9 parts of scorpio, 9-15 parts of earthworm, 9-15 parts of caulis sinomenii, 12-18 parts of bighead atractylodes rhizome, 12-18 parts of poria cocos, 9-15 parts of gentiana macrophylla, 12-18 parts of angelica sinensis, 20-40 parts of caulis spatholobi, 9-15 parts of rhizoma drynariae, 12-18 parts of radix paeoniae alba, 3-9 parts of honey-fried licorice root and 6-12 parts of rhizoma zingiberis. According to the traditional Chinese medicine composition for treating rheumatic arthritis, the medicine raw material composition of the traditional Chinese medicine composition for treating rheumatic arthritis is reasonably designed, four pathological links of cold, dampness, stasis and deficiency of rheumatic arthritis are covered through precise compatibility of monarch, minister, assistant and guide, and the traditional Chinese medicine composition has triple curative effects of anti-inflammatory analgesia, immunoregulation and bone protection.

The invention discloses Witzia ciliaris NCU-33 and application thereof, and belongs to the technical field of microbial medicines. The bacillus coagulans NCU-33 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the bacillus coagulans NCU-33 is CGMCC NO.31779. The strain is separated from a fresh excrement sample of healthy people; the strain is capable of ameliorating and / or preventing rheumatoid arthritis by anti-inflammatory and immunomodulatory effects.

The invention discloses a lindera glauca extract, a preparation method thereof and application of the lindera glauca extract in preparation of drugs for preventing and / or treating rheumatoid arthritis. The research finds that the lindera glauca extract can obviously reverse arthritic rat plantar part swelling and toe bending, relieve ankle joint injury, relieve synovial hyperplasia and inflammatory cell infiltration, inhibit joint fusion, relieve joint gap stenosis, relieve articular surface fusion tendency, increase bone mineral density and bone trabecula number, reduce bone trabecula separation degree and improve joint fusion. The lindera glauca extract can be used for relieving rheumatoid arthritis by protecting the inherent structure of joint tissues and improving inflammation, so that a novel natural medicine choice is provided for preventing and / or treating rheumatoid arthritis.

The invention provides a nitric oxide fluorescent probe with aggregation-induced emission characteristics and a preparation method and application thereof. The structural formula of the nitric oxide fluorescent probe is shown in the specification. The nitric oxide fluorescent probe provided by the invention is high in detection sensitivity, high in response speed, excellent in NO selectivity and AIE characteristic, wide in application range, not only suitable for liquid-phase and gas-phase NO detection, but also capable of realizing high-efficiency real-time detection of NO in body fluid, cells and living body samples, and wide in application prospect. The method can be used for diagnosis of diseases such as inflammation (rheumatoid arthritis), tumor microenvironment and the like, high-throughput drug screening and environment monitoring.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The invention relates to the field of traditional Chinese medicines, and discloses an embelia parviflora-containing traditional Chinese medicine for treating rheumatic arthritis and a preparation method of the embelia parviflora-containing traditional Chinese medicine. 10-20 parts of radix achyranthis bidentatae; 10-20 parts of ligusticum wallichii; 10-20 parts of radix paeoniae alba; 5-10 parts of fructus lycii; 5-10 parts of radix rehmanniae recen; the preparation method comprises the following steps: crushing embelia parviflora, radix achyranthis bidentatae, ligusticum wallichii, radix paeoniae alba, fructus lycii and radix rehmanniae recen; extracting medicinal components of the medicinal materials; the extracting solution is mixed with phospholipid or a polymer to form liposome, and the liposome is pH response type nano-liposome or temperature response type nano-liposome; preparing nano-liposome by a film hydration method or a layer-by-layer self-assembly method; and filtering and drying to obtain the traditional Chinese medicine. By using the pH response type nano-liposome and the temperature response type nano-liposome, the medicine can be accurately released to an inflammation area, the medicine is ensured to be only released at a place needing to be treated, and the treatment effect is improved.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38′ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.